1
As filed with the Securities and Exchange Commission on May 15, 2001
REGISTRATION NO. 333-56558
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDMENT NO. 2
TO
FORM S-3
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
INTERLEUKIN GENETICS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 94-3123681
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
135 BEAVER STREET, 2ND FLOOR
WALTHAM, MASSACHUSETTS 02452
(781) 398-0700
(Address, including zip code, and telephone number, including area
code, of registrant's principal executive offices)
FENEL M. ELOI
CHIEF FINANCIAL OFFICER, SECRETARY AND TREASURER
INTERLEUKIN GENETICS, INC.
135 BEAVER STREET, 2ND FLOOR
WALTHAM, MASSACHUSETTS 02452
(781) 398-0700
(Name, address, including zip code, and telephone number, including area code,
of agent for service)
Copies of all communications, including all communications sent to
the agent for service, should be sent to:
DARYL L. LANSDALE, JR., ESQ.
FULBRIGHT & JAWORSKI L.L.P.
300 CONVENT STREET, SUITE 2200
SAN ANTONIO, TEXAS 78205
(210) 270-9367
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: From time to
time after the effective date of this Registration Statement.
If the only securities being registered on this Form are being offered pursuant
to dividend or interest reinvestment plans, check the following box: [ ]
If any of the securities being registered on this Form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box: [X]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering.[ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box: [ ]
The Registrant hereby amends this Registration Statement on such date or
dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this Registration
Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the Registration Statement shall become
effective on such date as the Commission, acting pursuant to Section 8(a), may
determine.
2
P R O S P E C T U S
2,186,441 SHARES
INTERLEUKIN GENETICS, INC.
COMMON STOCK
The selling shareholders named on page 10 are offering up to 2,186,441
shares of our common stock. These shares include 728,814 shares issuable upon
the exercise of warrants to purchase common stock. We may receive up to
$2,202,544 upon the exercise of the warrants. The prices at which the selling
shareholders may sell these shares will be determined by the prevailing market
price for the shares or in negotiated transactions.
Our common stock is traded on The Nasdaq SmallCap Market and The Boston
Stock Exchange under the symbol "ILGN." On May 11, 2001, the last reported sale
price for our common stock on the Nasdaq SmallCap Market was $1.85 per share.
INVESTING IN OUR COMMON STOCK INVOLVES RISKS. SEE THE SECTION ENTITLED "RISK
FACTORS" BEGINNING ON PAGE 3.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
The date of this prospectus is May 15, 2001.
1
3
INTERLEUKIN GENETICS, INC.
We develop and sell genetic susceptibility tests, tests that identify
which individuals will respond to specific drug therapies and medical research
tools. We focus our efforts on discovering genetic factors that predict the
susceptibility of individuals to various diseases or determine which individuals
will respond to a specific drug therapy. We market PST(R) in the United States
and Europe. PST is our first genetic test and predicts the risk of periodontal
disease. Products under development include tests which predict the risk of
osteoporosis, coronary artery disease, diabetic retinopathy, asthma, pulmonary
fibrosis, and meningitis/sepsis.
Every living organism has a unique "genome," a master blueprint of all
the cellular structures and activities necessary to build and support life. A
genome is a map of the organism's DNA, which is in part comprised of segments
called "genes." Genes contain the specific sequences of information responsible
for particular physiological traits and processes. Each gene contains a sequence
of nucleotides which provide precise genetic instructions to create, or
"express" a protein. Proteins are the primary building blocks of an organism's
physiological characteristics. A typical human cell contains thousands of
different proteins essential to its structure, growth and function. If even one
gene or single nucleotide is abnormal, it can severely alter the cell's function
and result in a disease condition. Throughout the past decade, researchers have
focused on discovering genes and sequencing the human genome to determine the
order of nucleotides in a specific gene, permitting identification of the gene
and the protein it produces using a variety of techniques. For example,
scientists have used cDNA libraries, which contain copies of DNA with only the
expressed portion of the gene, in conjunction with computer software to identify
locations of genes within the genome. Recent advances have made these
technologies operate in a high-throughput manner, causing the discovery of genes
to become much more efficient and allowing researchers to focus on the
functional aspects of genes. Understanding the functional aspects of genes
permits the researchers to correlate those genes to medically relevant
conditions. The efforts to discover and understand these functional aspects of
the genes in the human genome are commonly referred to as "functional genomics."
Identifying genes that may predispose a person to a particular disease may allow
researchers to develop diagnostic tests for the disease permitting early
diagnosis and more successful treatment. We believe that combining genetic
susceptibility tests with specific therapeutic strategies results in improved
clinical outcomes and more cost-effective disease management.
We also develop and license our medical research tools to
pharmaceutical and biotech companies. For instance, BioFusion(R) is our
proprietary computer modeling system that simulates complex diseases and allows
researchers to identify useful information from the rapidly increasing genetic
information databases that companies and academic centers worldwide generate.
We work with collaborative partners at the basic discovery stage. We
use this strategy to obtain access to early-stage research and to reduce our
up-front research expenses. Since 1994, we have had a strategic alliance with
the Department of Molecular and Genetic Medicine at Sheffield University in the
United Kingdom. Sheffield provides us with the fundamental discovery and genetic
analysis from its research laboratories, and we focus on developing commercial
uses for these discoveries.
We distribute PST through third party distributors. The Straumann
Company and Kimball Genetics market PST in the United States and Puerto Rico.
Straumann is a leading supplier of dental implants, and Kimball has expertise in
processing genetic tests and analyzing their results. Hain Diagnostika/ADA GmbH
distributes PST in all countries outside of North America and Japan. Hain has
extensive experience in commercializing genetic tests in several fields, as well
as a specific commitment to marketing products directly to dentists. Sales of
PST have generated minimal revenues to date, and we do not know if or when PST
will achieve commercial acceptance.
We collaborate with the University of Washington School of Dentistry in
a study sponsored by Washington Dental Service. This study involves
administering 1,200 PSTs, and we believe it will provide scientific and
financial data regarding the use of PST as a treatment-planning tool to assess
risk before actual periodontal damage occurs. We anticipate the data from the
study will be available for analysis in 2001.
Our executive offices are located at 135 Beaver Street, Waltham,
Massachusetts 02452, and our telephone number is 781/398-0700. We incorporated
in Texas in 1986 and re-incorporated in Delaware in March 2000. We maintain a
website at www.ilgenetics.com. The contents of our website are not part of this
prospectus.
2
4
RISK FACTORS
An investment in our common stock involves a high degree of risk. You
should read this entire prospectus together with the information incorporated by
reference in this prospectus and you should give particular attention to the
following risk factors before deciding to purchase shares of our common stock.
WE HAVE A HISTORY OF OPERATING LOSSES AND EXPECT THESE LOSSES TO CONTINUE IN THE
FUTURE
We have experienced significant operating losses since our inception
and expect these losses to continue for the foreseeable future. We incurred
losses from operations of $0.7 million in fiscal year 1996, $4.1 million in
1997, $9.8 million in 1998, $6.2 million in 1999 and $5.2 million in 2000. As of
December 31, 2000, our accumulated deficit was $31.0 million. Our losses result
primarily from research and development and selling, general and administrative
expenses. We have not generated significant revenues from product sales, and we
do not know if we will ever generate significant revenues from product sales. We
will need to generate significant revenues to continue our research and
development programs and achieve profitability. We cannot predict when, if ever,
we will achieve profitability.
IF WE FAIL TO OBTAIN ADDITIONAL CAPITAL, OR OBTAIN IT ON UNFAVORABLE TERMS, THEN
WE MAY HAVE TO END OUR RESEARCH AND DEVELOPMENT PROGRAMS AND OTHER OPERATIONS
We anticipate that our current financial resources are adequate to
maintain our current and planned operations through July 2002. If we cannot
raise additional capital prior to July 2002, we will be unable to fund our
business operations and probably declare bankruptcy.
Our future capital needs depend on many factors. We will need capital
for the commercial launch of additional genetic tests, continued research and
development efforts, obtaining and protecting patents and administrative
expenses. Additional financing may not be available when needed, or, if
available, it may not be available on favorable terms. If we cannot obtain
additional funding on acceptable terms when needed, we may have to discontinue
operations, or, at a minimum, curtail one or more of our research and
development programs.
THE MARKET FOR GENETIC SUSCEPTIBILITY TESTS IS UNPROVEN
The market for genetic susceptibility tests is at an early stage of
development and may not continue to grow. Both we and the general scientific
community have only a limited understanding of the role of genes in predicting
disease. When we identify a gene or genetic marker that may predict disease, we
conduct clinical trials to confirm the initial scientific discovery and to
establish the scientific discovery's clinical utility in the marketplace. The
results of these clinical trials could limit or delay our ability to bring the
test to market, reduce the test's acceptance by our customers or cause us to
cancel the program, any of which limit or delay sales and cause additional
losses. The only genetic susceptibility test we currently market is PST, and it
has produced only minimal revenues to date. The marketplace may never accept our
products, and we may never be able to sell our products at a profit. We may not
complete development of or commercialize our other genetic susceptibility tests.
The success of our genetic susceptibility tests will depend upon their
acceptance as medically useful and cost-effective by patients, physicians,
dentists, other members of the medical and dental community and by third- party
payors, such as insurance companies and the government. We can achieve broad
market acceptance only with substantial education about the benefits and
limitations of genetic susceptibility tests. Our tests may not gain market
acceptance on a timely basis, if at all. If patients, dentists and physicians do
not accept our tests, or take a longer time to accept them than we anticipate,
then it will reduce our sales, resulting in additional losses.
3
5
WE RELY HEAVILY ON THIRD PARTIES TO PERFORM SALES, MARKETING AND DISTRIBUTION
FUNCTIONS ON OUR BEHALF, WHICH COULD LIMIT OUR EFFORTS TO SUCCESSFULLY MARKET
PRODUCTS
We have limited experience and capabilities with respect to
distributing, marketing and selling genetic susceptibility tests. We have relied
and plan to continue to rely significantly on sales, marketing and distribution
arrangements with third parties, over which we have limited influence. If these
third parties do not successfully market our products, it will reduce our sales
and increase our losses. If we are unable to negotiate acceptable marketing and
distribution agreements with future third parties, or if in the future we elect
to perform sales, marketing and distribution functions ourselves, we will incur
significant costs and face a number of additional risks, including the need to
recruit experienced marketing and sales personnel.
WE RELY HEAVILY ON THIRD PARTIES TO PERFORM RESEARCH AND DEVELOPMENT ON OUR
BEHALF, WHICH COULD LIMIT OUR EFFORTS TO SUCCESSFULLY DEVELOP PRODUCTS
We have limited research and development capabilities. In July 1999, we
entered into a new contractual arrangement with the University of Sheffield,
replacing the research and development agreement that had been in place since
1996. Under our arrangement with Sheffield, we will undertake the business
development and commercialization of discoveries resulting from Sheffield's
research. The agreement is non-cancellable for those discoveries on which we and
Sheffield have reached a specific business development agreement, but otherwise
either party can end the arrangement upon six months' notice. If Sheffield ends
our arrangement and we are unable to make alternative arrangements, our ability
to develop new products will be significantly diminished, causing us to
discontinue our operations. This agreement with Sheffield has a five-year term
with an automatic yearly renewal. As part of this arrangement, we issued an
aggregate of 475,000 shares of our common stock to Sheffield and its researchers
in exchange for patent rights and other interests held by Sheffield and its
researchers under our previous project agreements. Our agreement with Sheffield
requires us to fund agreed upon research and development activities at the
University of Sheffield on our behalf based upon annual budgets. This agreement
automatically renews in one-year increments. We also entered into a five-year
consulting agreement with Sheffield's key collaborator, Dr. Gordon Duff.
Reliance on third party research and development entails risks we would
not be subject to if we performed this function ourselves. These risks include
reliance on the third party for regulatory compliance and quality assurance, the
possibility of breach of the agreement by the third party because of factors
beyond our control and the possibility of termination or nonrenewals of the
agreement by the third party, based on its own business priorities, at a time
that is costly or inconvenient for us. We may in the future elect to perform our
own research and development, which will require us to raise substantial
additional funds and recruit additional qualified personnel.
IF WE ARE UNSUCCESSFUL IN ESTABLISHING ADDITIONAL STRATEGIC ALLIANCES, OUR
ABILITY TO DEVELOP AND MARKET PRODUCTS AND SERVICES WILL BE DAMAGED
Entering into strategic alliances for the development and
commercialization of products and services based on our discoveries is an
important element of our business strategy. We anticipate entering into
additional collaborative arrangements with Sheffield and other parties in the
future. We face significant competition in seeking appropriate collaborators. In
addition, these alliance arrangements are complex to negotiate and time-
consuming to document. If we fail to maintain existing alliances or establish
additional strategic alliances or other alternative arrangements, then our
ability to develop and market products and services will be damaged. In
addition, the terms of any future strategic alliances may be unfavorable to us
or these strategic alliances may be unsuccessful.
IF WE FAIL TO OBTAIN AN ADEQUATE LEVEL OF REIMBURSEMENT FOR OUR PRODUCTS OR
SERVICES BY THIRD PARTY PAYORS, THEN OUR PRODUCTS AND SERVICES WILL NOT BE
COMMERCIALLY VIABLE
The availability and levels of reimbursement by governmental and other
third party payors affect the market for any healthcare service. These third
party payors continually attempt to contain or reduce the costs of healthcare by
challenging the prices charged for medical products and services. Our ability to
successfully commercialize our existing genetic susceptibility tests and others
that we may develop depends on obtaining adequate reimbursement from third-party
payors. The extent of third-party payor reimbursement will likely heavily
influence physicians' and dentists' decisions to recommend genetic
susceptibility tests, as well as patients' elections
4
6
to pursue testing. If reimbursement is unavailable or limited in scope or
amount, then we cannot sell our products and services profitably. In particular,
third-party payors tend to deny reimbursement for services which they determine
to be investigational in nature or which are not considered "reasonable and
necessary" for diagnosis or treatment. To date, few third-party payors have
agreed to reimburse patients for genetic susceptibility tests, and we do not
know if third-party payors will, in the future, provide full reimbursement
coverage for these genetic tests. If third-party payors do not provide adequate
reimbursement coverage, then individuals may choose to directly pay for the
test. If both third-party payors and individuals are unwilling to pay for the
tests, then the number of tests we can sell will be significantly decreased,
resulting in reduced revenues and additional losses.
IF WE FAIL TO OBTAIN PATENT PROTECTION FOR OUR PRODUCTS AND PRESERVE OUR TRADE
SECRETS, THEN COMPETITORS MAY DEVELOP COMPETING PRODUCTS AND SERVICES, WHICH
WILL DECREASE OUR SALES AND MARKET SHARE
Our success will partly depend on our ability to obtain patent
protection, in the United States and in other countries, for our products and
services. In addition, our success will also depend upon our ability to preserve
our trade secrets and to operate without infringing upon the proprietary rights
of third parties.
We have 22 U.S. patent applications pending and a number of foreign
counterparts to these applications, including applications covering some of our
anticipated genetic susceptibility tests. Our patent positions, and those of
other pharmaceutical and biotechnology companies, are generally uncertain and
involve complex legal, scientific and factual questions. Our ability to develop
and commercialize products and services depends on our ability to:
- Obtain patents;
- Obtain licenses to the proprietary rights of others;
- Prevent others from infringing on our proprietary rights; and
- Protect trade secrets.
Our pending patent applications may not result in issued patents or any
issued patents may never afford meaningful protection for our technology or
products. Further, others may develop competing products which avoid legally
infringing upon, or conflicting with, our patents. In addition, competitors may
challenge any patents issued to us, and these patents may subsequently be
narrowed, invalidated or circumvented.
We also rely on trade secrets and proprietary know-how that we seek to
protect, in part, by confidentiality agreements. The third parties we contract
with may breach these agreements, and we might not have adequate remedies for
any breach. Additionally, our competitors may discover or independently develop
our trade secrets.
THIRD PARTIES MAY OWN OR CONTROL PATENTS OR PATENT APPLICATIONS AND REQUIRE US
TO SEEK LICENSES, WHICH COULD INCREASE OUR COSTS OR PREVENT US FROM DEVELOPING
OR MARKETING OUR PRODUCTS OR SERVICES
We may not have rights under patents or patent applications which are
related to our current or proposed products. Third parties may own or control
these patents and patent applications in the United States and abroad.
Therefore, in some cases, to develop or sell any proposed products or services,
with patent rights controlled by third parties, we or our collaborators may
seek, or may be required to seek, licenses under third-party patents and patent
applications. If this occurs, we will pay license fees or royalties or both to
the licensor. If licenses are not available to us on acceptable terms, we or our
collaborators may be prohibited from developing or selling our products or
services.
If third parties believe our products or services infringe upon their
patents, they could bring legal proceedings against us seeking damages or
seeking to enjoin us from testing, manufacturing or marketing our products or
services. Any litigation could result in substantial expenses to us and
significant diversion of attention by our technical and management personnel.
Even if we prevail, the time, cost and diversion of resources of patent
litigation would likely damage our business. If the other parties in any patent
litigation brought against us are successful, in addition to any liability for
damages, we may have to cease the infringing activity or obtain a license.
5
7
TECHNOLOGICAL CHANGES MAY CAUSE OUR PRODUCTS AND SERVICES TO BE OBSOLETE
Our competitors may develop susceptibility tests that are more
effective than our technologies or that make our technologies obsolete.
Innovations in the treatment of the diseases in which we have products or
product candidates could make our products obsolete. These innovations could
prevent us from selling, and significantly reduce or eliminate the markets for,
our products.
WE MAY BE DELISTED FROM NASDAQ RESULTING IN A LIMITED PUBLIC MARKET FOR OUR
COMMON STOCK AND VOLATILITY IN OUR STOCK PRICE
Our common stock is currently listed on the Nasdaq SmallCap Market and
the Boston Stock Exchange. During 1999, we received several notices from Nasdaq
stating that we were not in compliance with their continued listing
requirements. We believe that we currently comply with the continued listing
requirements, but we have not been notified by Nasdaq that we are in compliance.
Regardless, we may not be able to maintain our continued listing on the Nasdaq
or the Boston Stock Exchange.
If Nasdaq or the Boston Stock Exchange delists our shares, then trading
would be conducted in the over- the-counter market in the so-called "pink
sheets" or the OTC Bulletin Board. Selling our common stock will be more
difficult because of reduced trading volume and transaction size, transactions
could be delayed, and security analysts' and news media's coverage, if any, of
ILGN will be reduced. These factors may result in lower prices and larger
spreads in the bid and ask prices for our shares. The delisting of our shares
would also greatly impair our ability to raise additional necessary capital
through equity or debt financing.
Historically, our common stock has experienced low trading volumes. The
market price of our common stock also has been highly volatile, and it may
continue to be highly volatile, as has been the case with the securities of
other public biotechnology companies. Factors such as announcements by us or by
our competitors concerning technological innovations, new commercial products or
procedures, proposed government regulations and developments or disputes
relating to patents or proprietary rights are likely to affect the market price
of our common stock. Changes in the market price of our common stock may bear no
relation to our actual operational or financial results.
WE MAY BE PROHIBITED FROM FULLY USING OUR NET OPERATING LOSS CARRYFORWARDS,
WHICH COULD AFFECT OUR FINANCIAL PERFORMANCE
As a result of the losses incurred in 1998, 1999 and 2000, we have not
recorded a federal income tax provision for those years and have recorded a
valuation allowance against all future tax benefits. As of December 31, 2000, we
had net operating loss carryforwards of approximately $23.3 million for federal
income tax purposes, expiring in varying amounts through the year 2020. We also
had a research tax credit of approximately $317,000 at December 31, 2000, that
expires in varying amounts through the year 2020. Our ability to use these net
operating loss and credit carryforwards is subject to restrictions contained in
the Internal Revenue Code which provide for limitations on our utilization of
our net operating loss and credit carryforwards following a greater than 50%
ownership change during the prescribed testing period. We experienced a change
in ownership interest in June 1999. As a result, approximately $15.6 million of
our net operating loss carryforwards are limited in utilization to approximately
$825,000 annually. The annual limitation may result in the expiration of the
carryforwards prior to utilization.
WE ARE SUBJECT TO INTENSE COMPETITION FROM COMPANIES, WHICH MAY DAMAGE OUR
BUSINESS
Our industry is highly competitive. Our competitors in the United
States and abroad are numerous and include major pharmaceutical and diagnostic
companies, specialized biotechnology firms, universities and other research
institutions, including those receiving funding from the Human Genome Project.
Many of our competitors have considerably greater financial resources, research
and development staffs, facilities, technical personnel, marketing and other
resources than we do. Furthermore, many of these competitors are more
experienced than we are in discovering, commercializing and marketing products.
These greater resources may allow our competitors to discover important genes or
genetic markers before we do. If we, in conjunction with the University of
Sheffield, do
6
8
not discover disease predisposing genes and commercialize these discoveries
before our competitors, then our ability to generate sales and revenues will be
reduced or eliminated, and could make our products obsolete. We expect
competition to intensify in our industry as technical advances are made and
become more widely known.
WE ARE SUBJECT TO GOVERNMENT REGULATION WHICH MAY SIGNIFICANTLY INCREASE OUR
COSTS AND DELAY INTRODUCTION OF FUTURE PRODUCTS
The sale, performance or analysis of our genetic tests do not currently
require FDA or regulatory authority approval. Changes in existing regulations
could require advance regulatory approval of genetic susceptibility tests,
resulting in a substantial curtailment or even prohibition of our activities
without regulatory approval. If our genetic tests ever require regulatory
approval, then the costs of introduction will increase and marketing and sales
of products may be significantly delayed.
WE MAY BE SUBJECT TO PRODUCT LIABILITY CLAIMS THAT ARE COSTLY TO DEFEND AND THAT
COULD LIMIT OUR ABILITY TO USE SOME TECHNOLOGIES IN THE FUTURE
The design, development, manufacture and use of our genetic
susceptibility tests involve an inherent risk of product liability claims and
associated adverse publicity. Producers of medical products face substantial
liability for damages in the event of product failure or allegations that the
product caused harm. We currently maintain product liability insurance, but it
is expensive and difficult to obtain and may not be available in the future on
economically acceptable terms. We may become subject to product liability claims
which, even if they are without merit, could result in significant legal defense
costs. We could be held liable for damages in excess of the limits of our
insurance coverage, and any claim or resulting product recall could create
significant adverse publicity.
ETHICAL, LEGAL AND SOCIAL ISSUES RELATED TO GENETIC TESTING MAY REDUCE DEMAND
FOR OUR PRODUCTS
Genetic testing has raised issues regarding the appropriate utilization
and the confidentiality of information provided by genetic testing. Genetic
tests for assessing a person's likelihood of developing a chronic disease have
focused public attention on the need to protect the privacy of genetic
assessment medical information. For example, concerns have been expressed that
insurance carriers and employers may use these tests to discriminate on the
basis of genetic information, resulting in barriers to the acceptance of genetic
tests by consumers. This could lead to governmental authorities prohibiting
genetic testing or calling for limits on or regulating the use of genetic
testing, particularly for diseases for which there is no known cure. Any of
these scenarios would decrease demand for our products and result in substantial
losses.
OUR DEPENDENCE ON KEY EXECUTIVES AND SCIENTISTS COULD ADVERSELY IMPACT THE
DEVELOPMENT AND MANAGEMENT OF OUR BUSINESS
Our success substantially depends on the ability, experience and
performance of our senior management and other key personnel. If we lose one or
more of the members of our senior management or other key employees, it could
damage our development programs and our business. In addition, our success
depends on our ability to continue to hire, train, retain and motivate skilled
managerial and scientific personnel. The pool of personnel with the skill that
we require is limited. Competition to hire from this limited pool is intense. We
compete with numerous pharmaceutical and health care companies, as well as
universities and nonprofit research organizations in the highly competitive
Boston, Massachusetts business area. Loss of the services of Dr. Phillip J.
Reilly, our Chairman and CEO, Dr. Kenneth Kornman, our President, or Dr. Paul M.
Martha, our Chief Medical Officer, could delay our research and development
programs and damage our business. We have entered into employment agreements
with three to five year terms with Drs. Reilly, Kornman and Martha. Any of these
employees can terminate his employment upon 30 days notice. We do not maintain
key man life insurance on any of our personnel.
7
9
BECAUSE OUR PRINCIPAL SHAREHOLDERS, OFFICERS AND DIRECTORS CONTROL A LARGE
PERCENTAGE OF OUR VOTING POWER, OTHER STOCKHOLDERS' VOTING POWER MAY BE LIMITED
As of February 1, 2001, our directors, executive officers and certain
of their affiliates beneficially owned approximately 20% of our outstanding
common stock. Accordingly, these shareholders, individually and as a group, may
be able to influence the outcome of shareholder votes, including votes
concerning the election of directors, the adoption or amendment of provisions in
our Certificate of Incorporation or By-Laws and the approval of certain mergers
and other significant corporate transactions, including a sale of substantially
all of our assets. These shareholders may make decisions that are adverse to
other shareholders' interests. This ownership concentration may also adversely
affect the market price of our common stock.
WE DO NOT EXPECT TO PAY DIVIDENDS FOR THE FORESEEABLE FUTURE AND YOU SHOULD NOT
EXPECT TO RECEIVE ANY FUNDS WITHOUT SELLING YOUR SHARES, WHICH YOU MAY ONLY BE
ABLE TO DO AT A LOSS
We have never declared or paid any cash dividends on our capital stock.
We currently intend to retain any earnings for use in the operation and
expansion of our business and do not anticipate paying any cash dividends in the
foreseeable future. Therefore, you should not expect to receive any funds
without selling your shares, which you may only be able to do at a loss.
8
10
AVAILABLE INFORMATION
We file annual, quarterly and special reports, proxy statements and
other information with the Securities and Exchange Commission. You may read and
copy any reports, statements or other information that we file at the Securities
and Exchange Commission's Public Reference Room at 450 Fifth Street, N.W.,
Washington, D.C. 20549. Please call 1-800-SEC-0330 for further information on
the operation of Public Reference Room. Our Securities and Exchange Commission
filings are also available to the public at the Securities and Exchange
Commission's web site at http://www.sec.gov.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to "incorporate by reference" the information we file
with it, which means we can disclose important information to you by referring
you to those documents. The information incorporated by reference is considered
to be a part of this prospectus, except for any information that is superseded
by other information that is contained in this document or in later filed
documents incorporated by reference in this prospectus. We incorporate by
reference the documents listed below and any future filings we make with the
Securities and Exchange Commission under Section 13(a), 13(c), 14 or 15(d) of
the Securities Exchange Act of 1934 after the date of this prospectus and prior
to the time that all of the securities offered by this prospectus are sold.
(1) Our Annual Report on Form 10-K for the fiscal year ended
December 31, 2000;
(2) Our Current Report on Form 8-K filed March 7, 2001;
(3) Our Quarterly Report on Form 10-Q for the fiscal quarter ended
March 31, 2001; and
(4) The description of our common stock contained in Item 1 of our
Registration Statement on Form 8-A dated December 15, 1997.
You may request a copy of these filings, at no cost, by writing or
telephoning us at the following address:
Interleukin Genetics, Inc.
135 Beaver Street
Waltham, Massachusetts 02452
Attention: Investor Relations
Telephone: 781/398-0700
You should rely only on the information contained or incorporated by reference
in this prospectus or any prospectus supplement. We have not authorized anyone
to provide you with different information. You should not assume that the
information contained in this prospectus or any prospectus supplement is
accurate as of any date other than the date on the front of this prospectus. We
are not making an offer of our common stock in any state where the offer is
prohibited. In this prospectus,"Interleukin Genetics," "we," "our" and "us"
refer to Interleukin Genetics, Inc.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the documents incorporated by reference contain
forward-looking statements including, without limitation, statements concerning
our expectations of future sales, research and development expenses, selling,
general and administrative expenses, product introductions and cash
requirements. Forward-looking statements often, although not always, include
words or phrases such as "will likely result," "expect," "will continue,"
"anticipate," "estimate," "intend," "plan," "project," "outlook" or similar
expressions. Our actual results may vary materially from those expressed in
these forward-looking statements. Factors that could
9
11
cause actual results to differ from expectations include those contained in the
section entitled "Risk Factors." Our results of operations might be adversely
affected by one or more of these factors.
USE OF PROCEEDS
The shares being offered by this prospectus are owned by our
shareholders or may be issued upon the exercise of warrants held by our
shareholders. We may receive up to $2,202,544 upon exercise of the warrants. For
further information see the following section entitled "Selling Shareholders"
and the section entitled "Plan of Distribution" on page 11 of this prospectus.
SELLING SHAREHOLDERS
The following table presents information about the number of shares of
our common stock beneficially owned by each of the selling shareholders:
- the number of shares each selling shareholder beneficially owns as of
February 1, 2001;
- the percentage of our outstanding shares of common stock each selling
shareholder beneficially owns before this offering;
- the number of shares each selling shareholder is offering by this
prospectus;
- the number of shares each selling shareholder will beneficially own
after the completion of this offering; and
- the percentage of our outstanding shares of common stock each selling
shareholder will beneficially own after the completion of this
offering.
BENEFICIAL OWNERSHIP BENEFICIAL OWNERSHIP
BEFORE THE OFFERING AFTER THE OFFERING(1)
------------------- ---------------------
NUMBER PERCENTAGE SHARES BEING NUMBER PERCENTAGE
NAME OF SHARES OF CLASS(2) OFFERED OF SHARES OF CLASS
---- --------- ------------ ---------- ---------- --------
The Tail Wind Fund Ltd. 1,064,407(3) 5.1% 386,441(4) 677,966 3.3%
Special Situations Fund III L.P. 990,000 (5) 4.7% 990,000 (5) -0- -0-
Special Situations Private Equity
Fund L.P 480,000(6) 2.3% 480,000 (6) -0- -0-
Special Situations Cayman Fund L.P. 330,000(7) 1.6% 330,000 (7) -0- -0-
(1) Assumes all of the shares offered by this prospectus are sold and no
selling shareholder acquires any of our shares subsequent to the date
of this prospectus and prior to the completion of this offering.
(2) Based on 20,242,800 shares of common stock of the Company outstanding
as of February 1, 2001.
(3) Includes 264,407 shares of common stock issuable upon exercise of a
warrant.
(4) Includes 128,814 shares of common stock issuable upon exercise of a
warrant.
(5) Includes 330,000 shares of common stock issuable upon exercise of a
warrant.
(6) Includes 160,000 shares of common stock issuable upon exercise of a
warrant.
(7) Includes 110,000 shares of common stock issuable upon exercise of a
warrant.
In January 2001 we completed a private placement in which we issued
1,200,000 shares of our common stock and warrants to purchase up to 600,000
shares of our common stock to three of the selling shareholders. In addition, as
part of the terms of a private placement we completed in December 2000,
following the completion of the January 2001 private placement we issued an
additional 257,627 shares of our common stock and a warrant to purchase up to
128,814 shares of our common stock to a selling shareholder. All of these shares
are being offered by this prospectus. None of the selling shareholders has had a
material relationship with us within the past three years other than as a result
of their acquisition of our shares in these private placements.
10
12
PLAN OF DISTRIBUTION
We completed a private placement in January 2001 in which three of the
selling shareholders acquired 1,200,000 shares of our common stock and warrants
to purchase 600,000 shares of our common stock. Under the terms of a private
placement we completed in December 2000, following the January 2001 private
placement, we also issued 257,627 shares of our common stock and a warrant to
purchase 128,814 shares of our common stock to one of the selling shareholders.
We are registering all 2,186,441 of these shares on behalf of the selling
shareholders. We may receive up to $2,202,544 upon exercise of these warrants.
As used in this prospectus, the term "selling shareholders" includes the selling
shareholders named in the table on the previous page and donees, pledgees,
transferees or other successors-in-interest selling shares received from a
selling shareholder as a gift, pledge, partnership distribution or other
non-sale related transfer after the date of this prospectus. If we are notified
by a selling shareholder that a donee, pledgee, transferee or other
successor-in-interest intends to sell more than 500 shares, a supplement to this
prospectus will be filed.
Each selling shareholder will act independently of us in making
decisions with respect to the timing, manner and size of each sale. Each selling
shareholder may sell the shares from time to time and may also choose not to
sell all the shares they are allowed to sell by this prospectus. The sales may
be made on one or more exchanges or in the over-the-counter market or otherwise,
at terms and market prices prevailing at the time of the sale, at prices related
to the then prevailing market prices or in negotiated transactions, including an
underwritten offering or one or more of the following methods:
- a block trade in which the broker or dealer so engaged will
attempt to sell the shares as agent but may position and
resell a portion of the block as principal in order to
facilitate the transaction,
- purchases by a broker or dealer as principal and resale by the
broker or dealer for its account pursuant to this prospectus,
- an exchange distribution in accordance with the rules of an
exchange,
- ordinary brokerage transactions and transactions in which the
broker solicits purchasers, and
- privately negotiated transactions.
A selling shareholder may engage broker-dealers who in turn may arrange
for other broker-dealers to participate. Broker-dealers may receive commissions
or discounts from a selling shareholder in amounts to be negotiated immediately
prior to the sale. In addition, underwriters or agents may receive compensation
from a selling shareholder or from purchasers of the shares for whom they may
act as agents, in the form of discounts, concessions or commissions.
Underwriters may sell shares to or through dealers, and these dealers may
receive compensation in the form of discounts, concessions or commissions from
the underwriters or commissions from the purchasers for whom they act as agents.
Each selling shareholder, underwriter, broker, dealer and agent that
participates in the distribution of the shares may be deemed to be underwriters,
and any discounts or commissions received by them from a selling shareholder and
any profit on the resale of the shares by them may be deemed to be underwriting
discounts and commissions under the Securities Act of 1933.
To the extent required, we may amend or supplement this prospectus from
time to time to describe a specific plan of distribution, which amendment or
supplement will identify the aggregate amount of shares of our common stock
being offered and the terms of the offering. The amendment or supplement will
also disclose the following information:
- the name or names of any underwriters, dealers or agents,
- the purchase price paid by any underwriter for shares of our
common stock purchased from a selling shareholder,
- any discounts, commissions and other items constituting
compensation from a selling shareholder and/or Interleukin
Genetics, and
- any discounts, commissions or concessions allowed or reallowed
or paid to dealers, including the proposed selling price to
the public.
11
13
We have agreed to indemnify the selling shareholders in certain
circumstances against certain liabilities, including liabilities under the
Securities Act. The selling shareholders have agreed to indemnify us in certain
circumstances against certain liabilities, including liabilities under the
Securities Act.
The selling shareholders may enter into hedging transactions with
broker-dealers in connection with distributions of shares or otherwise. In these
transactions, broker-dealers may engage in short sales of shares in the course
of hedging the positions they assume with selling shareholders. The selling
shareholders also may sell shares short and redeliver shares to close out these
short positions. The selling shareholders may enter into option or other
transactions with broker-dealers which require the delivery of shares to the
broker-dealer. The broker- dealer may then resell or otherwise transfer these
shares pursuant to this prospectus. The selling shareholders also may loan or
pledge shares to a broker-dealer. The broker-dealer may sell the shares so
loaned, or upon a default the broker-dealer may sell the shares so pledged,
pursuant to this prospectus.
The selling shareholders also may resell all or a portion of shares of
our common stock being offered by this prospectus in open market transactions in
reliance upon Rule 144 under the Securities Act, provided it meets the criteria
and conforms to the requirements of this Rule.
Under applicable rules and regulations under the Exchange Act of 1934,
any person engaged in the distribution of shares may not simultaneously engage
in market making activities with respect to our common stock for a period of two
business days prior to the commencement of a distribution. In addition, each
selling shareholder will be subject to applicable provisions of the Exchange Act
of 1934 and the associated rules and regulations under the Exchange Act of 1934,
including Regulation M, which provisions may limit the timing of purchases and
sales of shares of our common stock by the selling shareholders. We will make
copies of this prospectus available to the selling shareholders. We have
informed them of the need for delivery of copies of this prospectus to
purchasers at or prior to the time of any sale of the shares.
In order to comply with certain states' securities laws, if applicable,
shares of our common stock will be sold in those states only through registered
or licensed brokers or dealers. Shares of our common stock may not be sold in
some states unless these shares have been registered or qualified for sale in
those states, unless an exemption from registration or qualification is
available and is obtained.
We are bearing all out-of-pocket expenses incurred in connection with
the registration of the resale of the shares of our common stock, including,
without limitation, all registration and filing fees imposed by the Securities
and Exchange Commission, The Nasdaq Stock Market, Inc. and blue sky laws,
printing expenses, transfer agents' and registrars' fees, and the fees and
disbursements of our outside counsel and independent public accountants. The
selling shareholders will bear all underwriting discounts and commissions and
transfer or other taxes.
DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION
FOR SECURITIES ACT LIABILITIES
Section 145 of the Delaware General Corporation Law or the DGCL,
provides that a Delaware corporation may indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or
investigative (a "proceeding") (other than an action by or in the right of the
corporation) by reason of the fact that he is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses
(including attorneys' fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by him in connection with such action, suit or
proceeding if he acted in good faith and in a manner he reasonably believed to
be in or not opposed to the best interests of the corporation, and, with respect
to any criminal action or proceeding, had no reasonable cause to believe his
conduct was unlawful. A Delaware corporation may indemnify any person under
Section 145 in connection with a proceeding by or in the right of the
corporation to procure judgment in its favor, as provided in the preceding
sentence, against expenses (including attorneys' fees) actually and reasonably
incurred by him in connection with the defense or settlement of such action,
except that no indemnification shall be made in respect thereof unless, and then
only to the extent that, a court of competent
12
14
jurisdiction shall determine upon application that such person is fairly and
reasonably entitled to indemnity for such expenses as the court shall deem
proper. A person is fairly and reasonably entitled to indemnity for such
expenses as the court shall deem proper. A Delaware corporation must indemnify
any person who was successful on the merits or otherwise in defense of any
action, suit or proceeding or in defense of any claim, issue or matter in any
proceeding, by reason of the fact that he is or was a director, officer,
employee or agent of the corporation or is or was serving at the request of the
corporation, against expenses (including attorneys' fees) actually and
reasonably incurred by him in connection with the proceeding. A Delaware
corporation may pay for the expenses (including attorneys' fees) incurred by an
officer or director in defending a proceeding in advance of the final
disposition upon receipt of an undertaking by or on behalf of such officer or
director to repay such amount if it shall ultimately be determined that he is
not entitled to be indemnified by the corporation.
Section 102(b)(7) of the DGCL permits a corporation to provide in its
certificate of incorporation that a director shall not be personally liable to
the corporation or its stockholders for monetary damages for a breach of
fiduciary duty as a director, except for liability (i) for any breach of the
director's duty of loyalty to the corporation or its stockholders, (ii) for any
acts or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (iii) in respect of certain unlawful dividend payments
or stock redemptions or repurchases, or (iv) for any transaction from which the
director derived an improper personal benefit. Article Six of our Certificate of
Incorporation eliminates the liability of directors to the fullest extent
permitted by the DGCL. The DGCL permits the purchase of insurance on behalf of
directors and officers against any liability asserted against directors and
officers and incurred by such persons in such capacity, or arising out of their
status as such, whether or not the corporation would have the power to indemnify
directors and officers against such liability.
We also have a policy insuring our directors and officers against
certain liabilities, including liabilities under the Securities Act.
Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors and officers and controlling persons as
described in the provisions above, we have been advised that, in the opinion of
the Commission, such indemnification is against public policy as expressed in
the Securities Act and is, therefore, unenforceable.
LEGAL MATTERS
The validity of the securities offered by this prospectus is being
passed upon by Fulbright & Jaworski L.L.P., counsel to Interleukin Genetics.
EXPERTS
The consolidated financial statements included in the Company's Annual
Report on Form 10-K for the years ended December 31, 1998, 1999 and 2000,
incorporated by reference in this prospectus and elsewhere in the registration
statement have been audited by Arthur Andersen LLP, independent public
accountants, as indicated in their reports with respect thereto, and are
included in this prospectus in reliance upon the authority of Arthur Andersen
LLP as experts in giving said reports.
13
15
WE HAVE NOT AUTHORIZED ANY PERSON TO MAKE A
STATEMENT THAT DIFFERS FROM WHAT IS IN THIS
PROSPECTUS. IF ANY PERSON DOES MAKE A STATEMENT
THAT DIFFERS FROM WHAT IS IN THIS PROSPECTUS, YOU
SHOULD NOT RELY ON IT. THIS PROSPECTUS IS NOT AN
OFFER TO SELL, NOR IS IT SEEKING AN OFFER TO BUY, OUR
COMMON STOCK IN ANY STATE IN WHICH THE OFFER OR
SALE IS NOT PERMITTED. THE INFORMATION IN THIS
PROSPECTUS IS COMPLETE AND ACCURATE AS OF ITS
DATE, BUT THE INFORMATION MAY CHANGE AFTER THAT
DATE.
2,186,441 SHARES
INTERLEUKIN GENETICS, INC.
COMMON STOCK
TABLE OF CONTENTS
PAGE
----
Interleukin Genetics, Inc................ 2
Risk Factors............................. 3
Available Information.................... 9
Incorporation of Certain Documents
by Reference........................... 9
Special Note Regarding Forward-Looking
Statements............................. 9
Use of Proceeds........................ 10
Selling Shareholders..................... 10
Plan of Distribution.................... 11
Disclosure of Commission Position on
Indemnification for Securities Act
Liabilities........................... 12
Legal Matters........................... 13
Experts................................. 13
P R O S P E C T U S
MAY 15, 2001
16
PART II
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
The estimated expenses in connection with this offering are:
Commission registration fee $1,279.07
Legal fees and expenses* 5,000.00
Miscellaneous* 500.00
-----------
Total $6,779.07
===========
* Estimated
The Company has agreed to pay all the costs and expenses of
this offering.
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Section 145 of the Delaware General Corporation Law (the "DGCL")
provides that a Delaware corporation may indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or
investigative (a "proceeding") (other than an action by or in the right of the
corporation) by reason of the fact that he is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses
(including attorneys' fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by him in connection with such action, suit or
proceeding if he acted in good faith and in a manner he reasonably believed to
be in or not opposed to the best interests of the corporation, and, with respect
to any criminal action or proceeding, had no reasonable cause to believe his
conduct was unlawful. A Delaware corporation may indemnify any person under such
Section in connection with a proceeding by or in the right of the corporation to
procure judgment in its favor, as provided in the preceding sentence, against
expenses (including attorneys' fees) actually and reasonably incurred by him in
connection with the defense or settlement of such action, except that no
indemnification shall be made in respect thereof unless, and then only to the
extent that, a court of competent jurisdiction shall determine upon application
that such person is fairly and reasonably entitled to indemnity for such
expenses as the court shall deem proper. A person is fairly and reasonably
entitled to indemnity for such expenses as the court shall deem proper. A
Delaware corporation must indemnify any person who was successful on the merits
or otherwise in defense of any action, suit or proceeding or in defense of any
claim, issue or matter in any proceeding, by reason of the fact that he is or
was a director, officer, employee or agent of the corporation or is or was
serving at the request of the corporation, against expenses (including
attorneys' fees) actually and reasonably incurred by him in connection
therewith. A Delaware corporation may pay for the expenses (including attorneys'
fees) incurred by an officer or director in defending a proceeding in advance of
the final disposition upon receipt of an undertaking by or on behalf of such
officer or director to repay such amount if it shall ultimately be determined
that he is not entitled to be indemnified by the corporation.
Section 102(b)(7) of the DGCL permits a corporation to provide in its
certificate of incorporation that a director shall not be personally liable to
the corporation or its stockholders for monetary damages for a breach of
fiduciary duty as a director, except for liability (i) for any breach of the
director's duty of loyalty to the corporation or its stockholders, (ii) for any
acts or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (iii) in respect of certain unlawful dividend payments
or stock redemptions or repurchases, or (iv) for any transaction from which the
director derived an improper personal benefit. Article Six of our Certificate of
Incorporation, eliminates the liability of directors to the fullest extent
permitted by Section 102(b)(7) of the DGCL. The DGCL permits the purchase of
insurance on behalf of directors and officers against any liability asserted
against directors and officers and incurred by such persons in such capacity, or
arising out of their status as such, whether or not the corporation would have
the power to indemnify directors and officers against such liability.
II-1
17
The Company also has a policy insuring its directors and officers
against certain liabilities, including liabilities under the Securities Act.
Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors and officers and controlling persons pursuant
to the foregoing provisions, the Company has been advised that, in the opinion
of the Commission, such indemnification is against public policy as expressed in
the Securities Act and is, therefore, unenforceable.
ITEM 16. EXHIBITS.
Exhibit No. Exhibit
----------- -------
5.1 Opinion of Fulbright & Jaworski L.L.P. regarding legality (previously filed)
23.1 Consent of Fulbright & Jaworski L.L.P. (previously filed)
23.2 Consent of Arthur Andersen LLP (filed herewith)
24.1 Power of Attorney (previously filed on signature page).
ITEM 17. UNDERTAKINGS.
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are
being made, a post-effective amendment to this registration statement to include
any material information with respect to the plan of distribution not previously
disclosed in the registration statement or any material change to such
information in the registration statement;
(2) That, for the purpose of determining any liability under
the Securities Act, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof; and
(3) To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the
termination of the offering.
(b) The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
Registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange
Act that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(c) The undersigned Registrant hereby undertakes that, insofar as
indemnification for liabilities arising under the Securities Act may be
permitted to directors, officers and controlling persons of the Registrant
pursuant to the foregoing provisions, or otherwise, the Registrant has been
advised that in the opinion of the Commission, such indemnification is against
public policy as expressed in the Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the
payment by the Registrant of expenses incurred or paid by a director, officer or
controlling person of the Registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the Registrant will, unless
in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue.
II-2
18
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended,
the Registrant certifies that it has reasonable grounds to believe that it meets
all the requirements for filing on Form S-3 and has duly caused this
registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Waltham and Commonwealth of Massachusetts the
14th day of May, 2001.
INTERLEUKIN GENETICS, INC.
By: /s/ Fenel M. Eloi
---------------------------------------
Fenel M. Eloi
Chief Financial Officer,
Secretary and Treasurer
Pursuant to the requirements of the Securities Act of 1933, as amended,
this Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
SIGNATURE TITLE DATE
--------- ----- ----
* Chairman of the Board and May 14, 2001
------------------------------------
Philip R. Reilly Chief Executive Officer
(Principal Executive Officer)
* President, Chief May 14, 2001
------------------------------------
Kenneth S. Kornman Scientific Officer
and a Director
/s/ Fenel M. Eloi Chief Financial Officer, May 14, 2001
------------------------------------
Fenel M. Eloi Secretary and Treasurer
(Principal Financial and
Accounting Officer)
* Director May 14, 2001
------------------------------------
Thomas A. Moore
* Director May 14, 2001
------------------------------------
Edward M. Blair, Jr.
* Director May 14, 2001
------------------------------------
Gary L. Crocker
* Director May 14, 2001
------------------------------------
John Garofalo
* by /s/ Fenel M. Eloi
-------------------------------------------
Fenel M. Eloi, as Attorney-in-Fact
II-3
19
EXHIBIT INDEX
EXHIBIT NO. EXHIBIT
---------- -------
5.1 Opinion of Fulbright & Jaworski L.L.P. (previously filed)
23.1 Consent of Fulbright & Jaworski L.L.P. (previously filed)
23.2 Consent of Arthur Andersen LLP (filed herewith)
24.1 Power of Attorney (previously filed on signature page)
II-4